MR findings in the amygdala/hippocampus and the time interval from the onset of neurological symptoms
| Time of Imaging with Reference to Symptom Onset | Imaging Findings in the Amygdala/Hippocampus | |||||||
|---|---|---|---|---|---|---|---|---|
| Plain CT | T1WI | T2WI | FLAIR | DWI | ADC Value | Gd-T1WI | Others on MR | |
| Abnormal findings | Low | High | High | High | Reduction | Abnormal enhancement | Atophic change | |
| Early period, days 1–2 (n = 4 patients) | 0/3 (0%) | 2/4 (50%) | 2/4 (50%) | 2/3 (67%) | 2/2 (100%) | 2/2 (100%) | 0/2 (0%) | 0/4 (0%) |
| Middle period, days 3–30 (n = 4 patients) | 5/6 (83%) | 4/6 (67%) | 5/6 (83%) | 3/5 (60%) | 1/3 (33%) | 0/2 (0%) | 2/6 (33%) | |
| Late period, days 31+ (n = 4 patients) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) | 0/2 (0%) | 0/2 (0%) | 4/4 (100%) | |
Note:—Gd-T1WI indicates gadolinium-diethylene triaminepentaacetic acid T1-weighted imaging; ADC, apparent diffusion coefficient; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; FLAIR, fluid-attenuated inversion recovery; DWI, diffusion-weighted imaging.